AXIM Biotech Launches For Research Use Only Sales for its COVID-19 Neutralizing Antibody Test SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye...

AXIM Biotechnologies Partners with Arizona State University to Determine Antibody Levels Against COVID-19 SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19...

Viome Named to the 2019 CB Insights Digital Health 150, List of Most Innovative Digital Health Startups SEATTLE, Oct. 02, 2019 (GLOBE NEWSWIRE) -- CB Insights today named Viome to the inaugural Digital Health 150 rankings, a list of the 150 most promising private digital health companies in the world....

Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza Engineered Skin substitute (ESS): Phase 1/ Early Phase 2 product candidate that has potential to be a revolutionary new treatment for severe burns ESS granted Orphan Drug designation and,...

Amarantus CEO Gerald Commissiong Elected to Biotechnology Industry Organization Committees SAN FRANCISCO and GENEVA, Oct. 20, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutics for...